Areal-world evaluation of indacaterol and other bronchodilators in COPD: The INFLOW study

Georges Juvelekian, Waleed El-Sorougi, Chaicharn Pothirat, Faisal Yunus, Teresita De Guia, Han Pin Kuo, Shalma Basu Patnaik, Virginia Pilipovic

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa. Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study. Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P,0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability. Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.

Original languageEnglish
Pages (from-to)2109-2120
Number of pages12
JournalInternational Journal of COPD
Volume10
Issue number1
DOIs
Publication statusPublished - Oct 5 2015
Externally publishedYes

Fingerprint

Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Physicians
Eastern Africa
Middle East
Far East
Nebulizers and Vaporizers
Forced Expiratory Volume
South Africa
indacaterol
Health Status
Prospective Studies
Safety
Tiotropium Bromide
Therapeutics

Keywords

  • Asia
  • Chronic obstructive pulmonary disease
  • Indacaterol
  • Long-acting bronchodilator
  • Middle East
  • Noninterventional study

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Juvelekian, G., El-Sorougi, W., Pothirat, C., Yunus, F., De Guia, T., Kuo, H. P., ... Pilipovic, V. (2015). Areal-world evaluation of indacaterol and other bronchodilators in COPD: The INFLOW study. International Journal of COPD, 10(1), 2109-2120. https://doi.org/10.2147/COPD.S83071

Areal-world evaluation of indacaterol and other bronchodilators in COPD : The INFLOW study. / Juvelekian, Georges; El-Sorougi, Waleed; Pothirat, Chaicharn; Yunus, Faisal; De Guia, Teresita; Kuo, Han Pin; Patnaik, Shalma Basu; Pilipovic, Virginia.

In: International Journal of COPD, Vol. 10, No. 1, 05.10.2015, p. 2109-2120.

Research output: Contribution to journalArticle

Juvelekian, G, El-Sorougi, W, Pothirat, C, Yunus, F, De Guia, T, Kuo, HP, Patnaik, SB & Pilipovic, V 2015, 'Areal-world evaluation of indacaterol and other bronchodilators in COPD: The INFLOW study', International Journal of COPD, vol. 10, no. 1, pp. 2109-2120. https://doi.org/10.2147/COPD.S83071
Juvelekian, Georges ; El-Sorougi, Waleed ; Pothirat, Chaicharn ; Yunus, Faisal ; De Guia, Teresita ; Kuo, Han Pin ; Patnaik, Shalma Basu ; Pilipovic, Virginia. / Areal-world evaluation of indacaterol and other bronchodilators in COPD : The INFLOW study. In: International Journal of COPD. 2015 ; Vol. 10, No. 1. pp. 2109-2120.
@article{a19e01a25dd044bfbdb417497530062c,
title = "Areal-world evaluation of indacaterol and other bronchodilators in COPD: The INFLOW study",
abstract = "Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa. Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study. Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59{\%} predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P,0.0001), 63{\%}–84{\%} of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63{\%}–80{\%} of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability. Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.",
keywords = "Asia, Chronic obstructive pulmonary disease, Indacaterol, Long-acting bronchodilator, Middle East, Noninterventional study",
author = "Georges Juvelekian and Waleed El-Sorougi and Chaicharn Pothirat and Faisal Yunus and {De Guia}, Teresita and Kuo, {Han Pin} and Patnaik, {Shalma Basu} and Virginia Pilipovic",
year = "2015",
month = "10",
day = "5",
doi = "10.2147/COPD.S83071",
language = "English",
volume = "10",
pages = "2109--2120",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Areal-world evaluation of indacaterol and other bronchodilators in COPD

T2 - The INFLOW study

AU - Juvelekian, Georges

AU - El-Sorougi, Waleed

AU - Pothirat, Chaicharn

AU - Yunus, Faisal

AU - De Guia, Teresita

AU - Kuo, Han Pin

AU - Patnaik, Shalma Basu

AU - Pilipovic, Virginia

PY - 2015/10/5

Y1 - 2015/10/5

N2 - Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa. Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study. Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P,0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability. Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.

AB - Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa. Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study. Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P,0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability. Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians.

KW - Asia

KW - Chronic obstructive pulmonary disease

KW - Indacaterol

KW - Long-acting bronchodilator

KW - Middle East

KW - Noninterventional study

UR - http://www.scopus.com/inward/record.url?scp=84943607194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943607194&partnerID=8YFLogxK

U2 - 10.2147/COPD.S83071

DO - 10.2147/COPD.S83071

M3 - Article

C2 - 26491281

AN - SCOPUS:84943607194

VL - 10

SP - 2109

EP - 2120

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

IS - 1

ER -